The likelihood of developing dementia at any given age has been decreasing for decades, even as the overall number of cases is expected to climb due to an aging population. Projections suggest that while new U.S. cases could reach one million annually by 2060, an 80-year-old today is significantly less likely to have dementia than someone of the same age a generation ago.
Declining Rates and Contributing Factors
Across wealthy nations, age-specific dementia rates have fallen by approximately 13 percent per decade since the late 1980s. This decline is largely attributed to factors that individuals can influence, including better management of blood pressure and cholesterol, reduced smoking rates, and increased years of education. The principle that brain health is closely linked to heart health is a key driver of this trend.
A 2024 Lancet commission estimated that up to 45 percent of dementia cases could be prevented or delayed by addressing 14 identified risk factors, with midlife being the most critical period for intervention, rather than old age. The recommended strategies include managing blood pressure and LDL cholesterol, avoiding smoking, maintaining physical activity, ensuring regular hearing and vision checks, continuous learning, and moderate alcohol consumption.
Historically, improvements in cardiovascular health, driven by advancements in medications for blood pressure and cholesterol, better management of heart disease and stroke, and a significant reduction in smoking, are believed to have positively impacted brain health. Despite increases in obesity and diabetes, many vascular risk factors have decreased concurrently with the fall in dementia prevalence.
The Shingles Vaccine Connection
Emerging research suggests a potential link between the shingles vaccine and a reduced risk of dementia. While the evidence is not yet conclusive and the vaccine is officially recommended for individuals aged 50 and over, a growing number of studies indicate a protective effect. A study in Wales found that older adults who received the shingles vaccine were 20 percent less likely to develop dementia in the subsequent seven years compared to unvaccinated individuals. This finding was strengthened by the study’s design, which utilized a natural experiment based on a birthday cutoff for vaccine eligibility.
Further research in Canada, involving hundreds of thousands of individuals over 70, corroborated these findings, showing a lower incidence of dementia among those who had received the shingles vaccine. A more recent analysis of the Welsh data also suggested that the vaccine might offer benefits beyond prevention, potentially slowing disease progression and reducing dementia-related deaths for those already diagnosed.
While current recommendations for the shingles vaccine focus on preventing the viral infection itself, the accumulating evidence regarding its potential neuroprotective benefits warrants further investigation and discussion between patients and healthcare providers. The current recombinant vaccine form has also been associated with even greater dementia protection in some studies compared to the older live-virus version used in earlier research.
Future Outlook
Dementia currently affects over 6 million Americans, with projections indicating a doubling of new cases by 2060. However, the ongoing decline in age-specific incidence rates offers a counterpoint to the rising overall numbers. Experts emphasize that while there is no cure for dementia today, the growing understanding of modifiable risk factors and promising research into interventions like the shingles vaccine suggest that individuals are not as helpless against these diseases as once believed.
Mitchell Landsberg is the senior reporter for News Raise and focuses on Technology. Mitchell regularly writes about social media platforms and how influencers, industry and general people use them to communicate and make money.
